Stockrabit · Analysts
Questions across 6 calls

Archit Joshi

Nuvama

Jubilant Ingrevia Limited

Jubilant Ingrevia Limited CC-May26.pdf · 2026-05-26
Hi. Good evening. Thanks a lot for taking my question and congrats on a good set of numbers. First one, trying a bit on the previous issue discussed by an earlier participant. What would be the building blocks for growth, not looking at it from a quarterly perspective, but on a yearly basis since there have been deliberations regarding the innovator contract with regards to their position in the global market. What is it that we fetch from them? Do we really have a clear path of recouping volumes if there has been a loss or a delay that we have seen in the beginning of the quarter, maybe because it started towards the end of March. Do we see that we might be able to execute the 60 million yearly trade with them in terms of revenues? That would be the first one. Second one, I will just club it up. So we have written that our pipeline in the pharma piece within the CDMO segment has gone up by 3x in 2 years and this is with innovators and Tier 1 CDMOs. So is there a scope of entrenching into some pharma majors also? And if there are any opportunities or rather tangible opportunities that you might want to highlight to us so that we can pencil in that kind of growth for FY'27 within CDMO. That would be it, sir?
Yes. I was just wanting to know the pipeline that we have built over the last 2 years, you have mentioned in the PPT that it is gone up by 3x, 3x rather. And with innovators and Tier 1 CDMOs, just wanted a better elaboration of that, whether this is something that is newly blowing up as a growth opportunity for us, pharma CDMO particularly because we have seen a few peers who are doing extremely well in the pharma intermediate side, making disproportionate margin. So, are we taking up that track over there? Or is it the same piece of Pyridine business that you used to cater to some of the large pharma guys? So how do we think about this, if you can help us understand?

PI Industries Limited

Navin Fluorine International Limited

Navin Fluorine International Limited CC-Feb26.pdf · 2026-02-09
Hi, good evening, sir. And thanks a lot for the opportunity and congrats on a great set of numbers. So just one question on CDMO. I think the MSA that you have signed with the first EU major, the final product of which continues to access newer geographies with the approvals and countries like China and is as recent as a week ago. Now, should that warrant for a market share to increase over a mid-term time frame, or the projections made for the final product are something that already are baked into what we expect as cGMP4 ramps up? One smaller, a different question to that. We have also spoken of another EU major where possibly future shipments can also ramp up and help us get closer to the $100 million mark in CDMO. Any developments that you would like to give us qualitatively to understand this better, the path of CDMO growth in the future. Thank you.
Sure, sir, got it. Sir, just the second part of my question is about the readout. I think you briefly touched upon that. Would there be anything more that we would like to know about it, or given where are we headed to, is there a solid expectation coming on that account as well, which will probably be another feather in our cap, second CDMO contract? So all ears on that, sir.

Clean Science and Technology Limited

Clean Science and Technology Limited CC-Feb26.pdf · 2026-01-31
Sir, first question on MEHQ. I mean you did explain quite well as to how MEHQ prices have come off. But sir, the entire let down in HQ prices would also be a function of phenol prices coming off. Would it be right to assume that with phenol maybe pricing cycle going higher, HQ prices will also eventually be on the higher side, and we will have the MEHQ prices also going upwards. So is this like a very transient situation? A slight extension to the same q uestion like you mentioned before. HQ also is used as a polymerization inhibitor. So is there a down-trading that is happening from MEHQ to HQ, which might have aided into this volume loss?
Got it. Got it. That's why the fluidity in the situation, I get your point. Sir, secondly, on the hydroquinone, catechol plan that we've had, and I believe we did have plans to have better yields of HQ and catechol compared to the competitors. Where would we be in that learning curve or have we already achieved that yield that you had expected earlier?
Clean Science and Technology Limited CC-Nov25.pdf · 2025-11-06
Hi, good evening, gentlemen. Just one question on understanding this entire competitive landscape and the second-degree impact that you spoke of. And if one could just understand what would be the sustainability of this given that some competition has emerged in China? Would it be that, because in all prices have been such significantly lower in the intern ational markets, it was thought of as an opportune thing to get into MEHQ, maybe in the Chinese markets, if you are confirming that. And is that also going in line with or in tandem with, let's say, the second-degree impact that we are facing from the US c ustomers that they have maybe a second or a third fiddle in the supply chain to China. So overall, maybe it could be transient in nature, let's say, this quarter or maybe third quarter that we are seeing to be flattish. But have we done any scenario analys is that if these prices or the competition continues to be aggressive at large, what would be the strategy for us to maintain the margins and volumes?
Sure sir, and the part on the competitive intensity of MEHQ, are there any other products also in our standalone business and how did it, I was wondering, how did it suddenl y emerge? Is it only because of phenol prices being that low, given that it's such a small market per se?

Aarti Industries Limited

Aarti Industries Limited CC-Nov25.pdf · 2025-11-07
Good set of numbers, firstly to start off with. So first one, just a near -term one. If I look at this quarter in isolation, and the INR 15 -20-odd crore EBITDA impacts that we had from the previous quarter, which I am assuming that would have been a part of this quarter. If I just make an adjustment, the EBITDA number should be roughly i n the range of INR270- 280-odd crore. Would this be like a steady -state number, let us say, a couple of quarters down the line before our Zone 4 and PEDA capacity is commissioned?
Sir, second one on the PEDA expansion. I believe it might be an opportune time to make PEDA given that we have an anti -dumping duty placed on Pretilachlor, I believe that would be the end product application of PEDA. Sir, we also had similar initiatives taken earlier from the ethylation unit for S - metolachlor earlier. Are we having any targeted approach towards agriculture given the family of products is similar? And do we have any export opportunities also in PEDA since I was just going through Pretilachlor’s market, it does not look like it is a big market in India, roughly 1,000- odd tonnes, and we already have one competitor with roughly 8,500 tonnes of capacity of PEDA. So could you explain the rationale and the supply/demand in the end product.